|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 伦理学与SARS:多伦多的教训显示文摘SARS的流行说明传染病在世界范围内流行是件多么容易的事,为了更好地应对下一次流行病,我们不仅要解决医学方面的问题,也同样需要解决伦理学方面的问题。 | Peter A Singer Solomon R Benatar Mark Bernstein Abdallah S Daar Bernard M Dickens Susan K MacRae Ross E G Upshur Linda Wright Randi Zlotnik Shaul 肖月 | 2004 | 英国医学杂志中文版2004，7，4： | 3 |
| 2 | Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians显示文摘 | Getchell Jane P Wroblewski Kelly E DeMaria Alfred Bean Christine L Parker Monica M Pandori Mark Dufour D Robert Busch Michael P Brecher Mark E Meyer William A Pesano Rick L Teo Chong-Gee Beckett Geoffrey A Araujo Aufra C Branson Bernard M D | 2013 | MMWR. Morbidity and Mortality Weekly Report2013，，18： | 3 |
| 3 | Extraction of gin- senosides from North American ginseng using modified supercritical carbon dioxide显示文摘 | Jeffery A Wood Mark A Bernards Wan-kei Wan | 2006 | The Journal of Supercfitical Fluids2006，39，1： | 1 |
| 4 | Multiple Criteria R&D Project Selection and Scheduling Using Fuzzy Logic显示文摘 | Mark A Coffin Bernard W Taylor | 1996 | Computers & Operations Research1996，，23： | 1 |
| 5 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 6 | Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation显示文摘 | Nikolai V Naoumov A.Ross Lopes Patrizia Burra Lucio Caccamo Rosa M Iemmolo Robert A de Man Margaret Bassendine John G O’Grady Bernard C Portmann Gaya Anschuetz Catherine A Barrett Roger Williams Mark Atkins | 2001 | Journal of Hepatology2001，，6： | 1 |
| 7 | Multiple criteria R&D project selection and scheduling using fuzzy logic 显示文摘 | Mark A C Bernard W T | 1996 | Computers & Operations Research1996，23，3： | 1 |
| 8 | How Useful Is the IQCODE for Discriminating between Alzheimer’s Disease, Mild Cognitive Impairment and Subjective Memory Complaints?显示文摘 | Sikkes Sietske A M Van Den Berg Mark T Knol Dirk L De Lange-de Klerk Elly S M Scheltens Philip Uitdehaag Bernard M J Klein Martin Pijnenburg Yolande A L | 2010 | Dementia and Geriatric Cognitive Disorders2010，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员